Bridge to Life has received FDA De Novo clearance for its VitaSmart hypothermic oxygenated perfusion (HOPE) system for liver ...
The market for organ preservation solutions is driven by rising transplant surgeries due to chronic illnesses and aging ...
The FDA clearance enables the commercial use of VitaSmart (TM) for hypothermic oxygenated perfusion of donor livers following static cold storage and prior to transplantation, providing a clear, ...
A clinical study shows that preoperative dynamic susceptibility contrast (DSC) perfusion magnetic resonance imaging (MRI) can ...
Bridge to Life gets US FDA De Novo clearance for VitaSmart HOPE System, the first device cleared in the US for hypothermic oxygenated perfusion of donor livers: Duluth, Georgia We ...
Normothermic machine perfusion (NMP) to preserve livers prior to transplant was associated with significantly improved clinical outcomes and reduced use of hospital resources compared with static cold ...
A study led by scientists at the Centro Nacional de Investigaciones Carlos III (CNIC) demonstrates that stroke severity ...
In OHCA survivors, longer elevated perfusion pressure duration with MAP >80 mmHg in the first 48 hours after ROSC was ...
Bridge to Life™ Ltd., a global innovator in organ preservation and perfusion technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted De Novo clearance for the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback